$38.72
+0.93(2.45%)
Mkt Cap $2.3B
$14.91
$39.29
52-Week Range
At A Glance
1
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
2
Most recently: . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment (2026-01-07).
$2.3B
Market Cap
—
Revenue
-$109M
Net Income
Employees62
Fundamentals
How The Business Makes Money
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001672619
ISINUS29337E1029
CUSIP29337E102
Phone720 647 8519
Address6200 Lookout Road, Boulder, CO, 80301, US
SEC EDGAR